New combo therapy targets Hard-to-Treat leukemia
NCT ID NCT06445959
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 23 times
Summary
This study is for people with acute myeloid leukemia (AML) that has a specific genetic change called an IDH1 mutation. It tests a combination of three drugs: decitabine, venetoclax, and olutasidenib. The goal is to find a safe dose and see if the combination helps control the disease. About 78 adults with AML that has returned, not responded to treatment, or who cannot have strong chemotherapy will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUTANT IDH1 INHIBITOR OLUTASIDENIB are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Roswell Park
RECRUITINGBuffalo, New York, 14263, United States
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.